AVBP
ArriVent BioPharma, Inc. Common Stock (AVBP) Risks & Opportunities Analysis (2026)
Overall Score
Balance Sheet Liquidity
Very high liquidity with a current ratio of 14.16x and cash ratio of 5.56x.
Leverage remains minimal, with debt-to-equity at 0.001x and debt-to-assets at 0.001x.
Net current asset value of $366.3M and tangible book value per share of $7.71 provide downside support.
Profitability Cash Flow
Trailing margins remain unprofitable, with EBITDA, EBIT, and net profit margins all at 0% and net income per share at -$3.44.
Cash generation is negative, with operating cash flow per share at -$3.11 and free cash flow per share at -$3.11.
Returns remain deeply negative, including ROE of -50.3% and ROIC of -47.9%.
Valuation Downside Protection
The stock screens at a low EV of $1.22B versus a market cap of $1.37B, but valuation is distorted by negative earnings and cash flow.
Price-to-book is 3.83x, while book value per share is $7.71 and cash per share is $7.84.
Net current asset value of $366.3M and tangible asset value of $366.8M offer some asset-backed support despite weak operating performance.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ArriVent BioPharma, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

